Intervention

Insulin Glargine 300 UNT/ML [Toujeo]

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting0

Common conditions4

Lead sponsors shown2

Clinical trials

2 shown

Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical CareNCT05155917 · 2022-03-01

UNKNOWN

Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mLNCT05109520 · 2021-09-08

COMPLETED

Common conditions

Diabetic Ketoacidosis1 Hyperglycaemic Crisis in Diabetes Mellitus1 Hyperglycaemic Hyperosmolar Nonketotic Syndrome1 Type 1 Diabetes1

Leading sponsors

Changhua Christian Hospital 1 prof dr Pieter Gillard 1

Trial status mix

COMPLETED1

UNKNOWN1

Phase mix

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.